• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Acoramidis Gets Positive CHMP Nod For ATTR-CM Treatment

    GLOBENEWSWIRE

    Unnatural Products Announces BridgeBio Option for Macrocyclic

    GLOBENEWSWIRE

    BridgeBio Selects PANTHERx® for Attruby™ Distribution

    PR NEWSWIRE

    Orsini Selected by BridgeBio as Pharmacy for ATTRUBY™ Treatment

    PR NEWSWIRE

    Look out, Pfizer: BridgeBio gains `best-case` FDA nod for Attruby

    FIERCE PHARMA

    US FDA approves BridgeBio`s drug for rare heart condition

    PRESS RELEASE

    BridgeBio Oncology Appoints Praveen to its Board of Directors

    BUSINESSWIRE

    BridgeBio Publishes Infigratinib Study for Achondroplasia in NEJM

    GLOBENEWSWIRE

    Acoramidis Shows Sustained Cardiovascular Benefit & Reduce in ACM

    GLOBENEWSWIRE

    BridgeBio touts extension study data for ATTR-CM drug acoramidis

    FIERCE BIOTECH

    BridgeBio Pharma Reports Q3 2024 Financial Results & Update

    GLOBENEWSWIRE

    BridgeBio Oncology Doses First Patient in Phase 1 BREAKER-101 Trial

    BUSINESSWIRE

    BridgeBio Shares Data From CANaspire Study For Canavan Disease

    GLOBENEWSWIRE

    BridgeBio To Show 42-Month Acoramidis Data At AHA 2024

    GLOBENEWSWIRE

    BridgeBio Shares Recurrent Event Analysis Of ATTRibute-CM Study

    GLOBENEWSWIRE

    BridgeBio`s Infigratinib Gets Breakthrough Therapy Status

    GLOBENEWSWIRE

    BridgeBio Reports Phase 1/2 Results For CAH Gene Therapy

    GLOBENEWSWIRE

    BridgeBio`s BBP-812 Receives FDA`s RMAT Designation For Canavan

    GLOBENEWSWIRE

    BridgeBio to stop development of therapy for genetic disorder

    REUTERS

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    Alnylam shares slide after heart drug data fails to impress investors

    REUTERS

    BridgeBio Shares Data On Serum TTR Increase With Acoramidis

    GLOBENEWSWIRE

    BridgeBio to Present Additional Analyses from ATTRibute-CM Trial at ESC Congress

    GLOBENEWSWIRE

    BridgeBio Pharma to Participate in September Investor Events

    GLOBENEWSWIRE

    BridgeBio Partners with CarDS Lab for AI-Enhanced ATTR-CM Diagnosis

    GLOBENEWSWIRE

    BridgeBio Partners With CarDS Lab To Improve ATTR-CM Diagnosis Using AI

    GLOBENEWSWIRE

    BridgeBio Launches Offshoot With $300M For Genetic Disease Programs

    FIERCE BIOTECH

    BridgeBio Launches MyAchonJourney Resource For Achondroplasia Families

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio Reports Q2 2024 Results And Business Update

    GLOBENEWSWIRE

    BridgeBio Appoints Thomas Trimarchi As President And COO

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio Receives FDA Designation For BBP-418 In LGMD2I/R9

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio To Participate In Goldman Healthcare Conference

    GLOBENEWSWIRE

    BridgeBio Doses First KRASG12C NSCLC Patient With BBO-8520 In ONKORAS Trial

    BUSINESSWIRE

    BridgeBio data show sustained benefit for achondroplasia drug

    BIOPHARMADIVE

    BridgeBio: Durable Infigratinib Results In Achondroplasia Study

    GLOBENEWSWIRE

    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call

    GLOBENEWSWIRE

    Acoramidis Increases Transthyretin Tied To Better Cardiac Outcomes In ATTR-CM

    GLOBENEWSWIRE

    BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial

    ENDPTS

    Bridgebio Acoramidis Attr-Cm Analysis: Phase 3 Attribute-Cm At Isa 2024

    GLOBENEWSWIRE

    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma

    FDA

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio To Participate In BofA Global Healthcare Conference 2024

    GLOBENEWSWIRE

    BridgeBio Presents ATTR-CM Data, Acoramidis Reduced Mortality In SA

    GLOBENEWSWIRE

    BridgeBio spins out oncology unit with $200M in backing for RAS assets

    ENDPTS

    BridgeBio Pharma Reports First Quarter 2024 Financial Results

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio Presents Data of ATTRibute-CM Ph 3 Study with Transthyretin ATTR-CM

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    bridgebio pharma announces pricing of public offering of common stock

    PRESS RELEASE

    Bayer buys European rights to BridgeBio`s ATTR-CM pill

    ENDPTS

    BridgeBio Pharma Announces Proposed Public Offering of Common Stock

    GLOBENEWSWIRE

    BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib

    FIERCE PHARMA

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    GLOBENEWSWIRE

    BridgeBio Pharma Announces FDA Acceptance of NDA for Acoramidis

    GLOBENEWSWIRE

    BridgeBio Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis

    GLOBENEWSWIRE

    Invitae Partners with BridgeBio Pharma to Harness Genetic Insights

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.